Zhiyong Guo, Yao Liu, Qi Ling, Leibo Xu, Tielong Wang, Jiaxing Zhu, Yimou Lin, Xinjun Lu, Wei Qu, Fan Zhang, Zhijun Zhu, Jian Zhang, Zehua Jia, Ping Zeng, Wenjing Wang, Qiang Sun, Qijie Luo, Zemin Hu, Zhouying Zheng, Yingbin Jia, Jian Li, Yujian Zheng, Mengchao Wang, Shaoping Wang, Zemin Han, Sheng Yu, Chuanjiang Li, Shuhua Zhang, Jun Xiong, Feiwen Deng, Ying Liu, Huanwei Chen, Yanfeng Wang, Ling Li, Wenjin Liang, Andrea Schlegel, Nashan Björn, Chao Liu, Shusen Zheng, Xiaoshun He
Immune checkpoint inhibitors (ICIs) as a downstaging or bridging therapy for liver transplantation (LT) in hepatocellular carcinoma (HCC) patients is rapidly increasing. However, the evidence about the feasibility and safety of pre-LT ICIs therapy is limited and controversial. To this end, a multicenter, retrospective cohort study was conducted in 11 Chinese centers. The results showed that 83 recipients received pre-LT ICIs therapy during the study period. The median post-LT follow up was 8.1 (interquartile range [IQR] 3...
April 18, 2024: American Journal of Transplantation